XML 57 R26.htm IDEA: XBRL DOCUMENT v3.10.0.1
Parent entity financial information
 12 Months Ended
Jun. 30, 2018
Disclosure Of Parent Entity Financial Information [Abstract]  
Parent entity financial information

20. Parent entity financial information

a.

Summary financial information

The parent entity financial information disclosure is an Australian Disclosure Requirement as required by Corporations Regulations 2001. The individual financial statements for the parent entity show the following aggregate amounts:

 

 

 

As of June 30,

 

(in U.S. dollars, in thousands)

 

2018

 

 

2017

 

Balance Sheet

 

 

 

 

 

 

 

 

Current Assets

 

 

19,499

 

 

 

7,276

 

Total Assets

 

 

676,385

 

 

 

666,357

 

 

 

 

 

 

 

 

 

 

Current Liabilities

 

 

6,086

 

 

 

6,400

 

Total Liabilities

 

 

6,186

 

 

 

6,815

 

 

 

 

 

 

 

 

 

 

Shareholders' Equity

 

 

 

 

 

 

 

 

Issued Capital

 

 

889,480

 

 

 

830,424

 

Reserves

 

 

 

 

 

 

 

 

    Foreign Currency Translation Reserve

 

 

(174,948

)

 

 

(146,840

)

    Share Options Reserve

 

 

61,320

 

 

 

55,265

 

(Accumulated losses)

 

 

(105,653

)

 

 

(79,307

)

 

 

 

670,199

 

 

 

659,542

 

 

 

 

 

 

 

 

 

 

Loss for the period

 

 

(26,346

)

 

 

(24,216

)

Total comprehensive loss for the period

 

 

(26,346

)

 

 

(24,216

)

 

b.

Contingent liabilities of the parent entity

(i) Central Adelaide Local Health Network Incorporated (“CALHNI”) (formerly Medvet)

Mesoblast Limited acquired certain intellectual property relating to our MPCs, or Medvet IP, pursuant to an Intellectual Property Assignment Deed, or IP Deed, with Medvet Science Pty Ltd, or Medvet. Medvet’s rights under the IP Deed were transferred to Central Adelaide Local Health Network Incorporated, or CALHNI, in November 2011. In connection with its use of the Medvet IP, on completion of certain milestones Mesoblast Limited will be obligated to pay CALHNI, as successor in interest to Medvet, (i) certain aggregated milestone payments of up to $2.2 million and single-digit royalties on net sales of products covered by the Medvet IP, for cardiac muscle and blood vessel applications and bone and cartilage regeneration and repair applications, subject to minimum annual royalties beginning in the first year of commercial sale of those products and (ii) single-digit royalties on net sales of the specified products for applications outside the specified fields.